close
Patient InformationDownloadPrescribing InformationDownloadFor Healthcare Providers

The ONLY FDA-Approved Treatment for Reducing Excess Abdominal Fat in Adults with HIV and Lipodystrophy*

A Different Kind of Treatment for a Different Kind of Fat

* EGRIFTA WR™ is not for weight loss management. The long-term safety of EGRIFTA WR™ on the heart and blood vessels (cardiovascular) is not known. It is not known whether taking EGRIFTA WR™ helps improve how well you take your antiretroviral medications. It is not known if EGRIFTA WR™ is safe and effective in children; do not use EGRIFTA WR™ in children.

Think you may have excess visceral abdominal fat (EVAF)? 

Take a quick survey to find out

If your responses suggest you may be at risk, we’ll reach out to answer any questions you might have and provide more information about this condition and treatment options—so you can have an informed discussion about EVAF with your healthcare provider.

Stock photography. Posed by model.

What is EGRIFTA WR™?

EGRIFTA WR™ is a prescription medicine used to reduce excess visceral abdominal (belly) fat in adults with HIV and lipodystrophy.*
* EGRIFTA WR™ is not for weight loss management. The long-term safety of EGRIFTA WR™ on the heart and blood vessels (cardiovascular) is not known. It is not known whether taking EGRIFTA WR™ helps improve how well you take your antiretroviral medications. It is not known if EGRIFTA WR™ is safe and effective in children; do not use EGRIFTA WR™ in children.

EVAF is not like regular fat

Weight gain typically occurs when regular fat (also known as subcutaneous fat) builds up beneath your skin. This type of fat tends to feel “pinchable” or squishy. But if you notice a firmness deeper in your abdomen, it could be EVAF. EVAF in people with HIV can be difficult to control with diet and exercise alone.
Stock photography. Posed by model.
Stock photography. Posed by model.

Explore the THERA patient support® Program

THERA patient support® is a comprehensive patient support program offering personalized services and a dedicated team that will support you at every step of your EGRIFTA WR™ treatment journey.

What is EGRIFTA WR™ (tesamorelin) for injection?

  • EGRIFTA WR™ is a prescription medicine used to reduce the excess stomach-area (abdominal) fat in adults with HIV and lipodystrophy.
  • EGRIFTA WR™ is a growth hormone-releasing factor (GHRF) analog.
  • EGRIFTA WR™ is not for weight loss management.
  • The long-term safety of EGRIFTA WR™ on the heart and blood vessels (cardiovascular) is not known.
  • It is not known whether taking EGRIFTA WR™ helps improve how well you take your antiretroviral medications.
  • It is not known if EGRIFTA WR™ is safe and effective in children; do not use EGRIFTA WR™ in children.

You should not take EGRIFTA WR™ if you:

  • Have a pituitary gland tumor, surgery, or other problems related to your pituitary gland, or have had radiation treatment to your head or head injury.
  • Have active cancer.
  • Are allergic to tesamorelin or any of the ingredients in EGRIFTA WR™.
  • Are pregnant or become pregnant. If you become pregnant, stop using EGRIFTA WR™ and talk with your healthcare provider.
  • Are less than 18 years of age.

Before using EGRIFTA WR™ tell your healthcare provider if you:

  • Have or have had cancer.
  • Have problems with blood sugar or diabetes.
  • Have scheduled heart or stomach surgery.
  • Have breathing problems.
  • Are breastfeeding or plan to breastfeed.
  • Are taking any other prescription and non-prescription medicines, vitamins, and herbal supplements.

EGRIFTA WR™ may cause serious side effects including:

  • Increased risk of new cancer in adults with HIV or your cancer coming back (reactivation). Stop using EGRIFTA WR™ and inform your healthcare provider if any cancer symptoms come back.
  • Increased levels of your insulin-like growth factor-1 (IGF-1). Your healthcare provider will do blood tests to check your IGF-1 levels while you are taking EGRIFTA WR™.
  • Serious allergic reaction such as rash or hives anywhere over the body or on the skin, swelling of the face or throat, shortness of breath or trouble breathing, fast heartbeat, feeling of faintness or fainting, itching and reddening or flushing of the skin. If you have any of these symptoms, stop using EGRIFTA WR™ and get emergency medical help right away.
  • Swelling or fluid retention. Call your healthcare provider if you have swelling, an increase in joint pain, or pain or numbness in your hands or wrists.
  • Increase in blood sugar (glucose) or diabetes.
  • Injection site reactions. Injection site reactions are a common side effect of EGRIFTA WR™ but may sometimes be serious.
  • Increased risk of death in people who have critical illness because of heart or stomach surgery, trauma or serious breathing (respiratory) problems has been reported after treatment with therapeutic doses of growth hormone.

The most common side effects of EGRIFTA WR™ include:

  • Pain in legs and arms
  • Muscle pain

These are not all the possible side effects of EGRIFTA WR™. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or to TPS logo toll-free at 1-833-23THERA (1-833-238-4372).

This information is not intended to replace discussions with your doctor. For additional information about EGRIFTA WR™, see the Patient Information and Patient Instructions for Use, and talk to your doctor. For more information about EGRIFTA WR™ contact TPS logo toll-free at 1-833-23THERA (1-833-238-4372).